Interim Analysis Expected End of 2Q 2025BETHESDA, MD, Mar 14, 2025 - (ACN Newswire) - Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading ...

Researchers from Liverpool School of Tropical Medicine (LSTM) have completed a Phase I clinical trial for a new oral ...

After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...

The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single ...

Anocca AB, a leading T-cell immunotherapy company, announces the authorisation of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

We are thrilled to share that the first trial site has been initiated and activation of additional clinical sites continues,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS ...

The Phase 2b ICONA clinical trial was a 52-week randomized, double-blind, placebo-controlled trial that evaluated the safety and histological impact of icosabutate at 300 and 600 mg compared to ...